Drug Profile
Pasotuxizumab - Amgen/Bayer HealthCare Pharmaceuticals
Alternative Names: AMG-212; BAY-2010112; MT-112; PSMA BiTE AntibodyLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Micromet Inc
- Developer Amgen; Bayer HealthCare Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fv fragments; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Prostate-cancer(Hormone refractory, Late-stage disease) in Austria (IV, Infusion)
- 28 May 2021 No recent reports of development identified for phase-I development in Prostate-cancer(Hormone refractory, Late-stage disease) in Austria (SC, Injection)
- 28 May 2021 No recent reports of development identified for phase-I development in Prostate-cancer(Hormone refractory, Late-stage disease) in Germany (IV, Infusion)